Search Results for: 150

— SYN-004 Degraded IV Ceftriaxone in the Presence of a Proton Pump Inhibitor in the Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — Two Poster Presentations Planned for ASM Microbe 2016, Including Detailed Data from Two SYN-004 Phase 2a Open-Label Clinical Trials — ROCKVILLE, Md., May16, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE […]

— SYN-004 Degraded IV Ceftriaxone in Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — First Patients Dosed in Phase 2b Proof-of-Concept Clinical Trial for SYN-004 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE

Collaboration Targets Delivery of an Essential Enzyme via ActoBiotics™ Platform without Adverse Impact on Gut Microbiome GERMANTOWN, Md. and ROCKVILLE, Md., Aug. 10, 2015 /PRNewswire/ — Intrexon Corporation (NYSE:XON), a leader in synthetic biology, and Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,

— Company Completes $18.9 Million Net Registered Direct Offering; Finalizes Plans for Start of Clinical Trials in C. difficile and C-IBS — — Conference Call Today, November 14, 2014, at 8:30 a.m. (EST); U.S. Participants Call (888) 347-5280 or Join Webcast at http://www.videonewswire.com/event.asp?id=100975 — ROCKVILLE, Md., Nov. 14, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: